Click here to listen to today’s Diabetes Health in the News Podcast!
In late September 2015, the FDA finally approved Tresiba, a diabetes drug from Novo Nordisk. This once daily medication is a long-acting drug that was previously rejected in 2013 after the FDA requested more data about the heart risks associated with Tresiba.
The medication is currently sold in 30 countries and is expected to launch in the U.S. in early 2016.
The FDA also approved Ryzodeg from Novo Nordisk. Ryzodec combines a long-acting insulin analog with a rapid-acting human insulin analog
Tresiba and Ryzodec are injected once or twice daily and can be used for both Type 1 and Type 2 diabetes treatments.
These findings were published by the FDA on September 25, 2015.